Results 41 to 50 of about 1,341 (168)

Severe Hyperglycemia with Teprotumumab for Treatment of Thyroid Eye Disease

Case Reports in Ophthalmology
Introduction: Thyroid eye disease (TED) is a rare condition involving autoimmune-mediated inflammation of the orbit and periocular structures, which can result in many debilitating symptoms.
Savannah Cottom, Brayden Barrientez, Andrew Melson   +2 more
doaj   +1 more source

Precision Medicine in Graves’ Disease and Ophthalmopathy

Frontiers in Pharmacology, 2021
Graves’ disease (GD) is a condition caused by an autoimmune process involving the thyroid gland, whose main outcome is hyperthyroidism. TSAb start the autoimmune process stimulating the overproduction of thyroid hormones.
Giusy Elia, Poupak Fallahi, Francesca Ragusa, Sabrina Rosaria Paparo, Valeria Mazzi, Salvatore Benvenga, Salvatore Benvenga, Salvatore Benvenga, Alessandro Antonelli, Silvia Martina Ferrari   +9 more
doaj   +1 more source

TSHR‐Targeting Nucleic Acid Aptamer Treats Graves' Ophthalmopathy via Novel Allosteric Inhibition

Advanced Science, Volume 13, Issue 4, 19 January 2026.
This study presents YC3, a novel inhibitory TSHR‐targeting aptamer, as a promising therapeutic for Graves' ophthalmopathy (GO). YC3 suppresses pathological phenotypes in human orbital fibroblasts and improves outcomes in GO mice by binding to a previously unidentified allosteric site on TSHR, demonstrating the potential of aptamers in advancing ...
Yanchen Zhang, Ende Wu, Weibin Liu, Ling Zeng, Neng Ling, Hongmei Wang, Zhixing Li, Shuang Yao, Tonghe Pan, Xuanwen Li, Yate Huang, Xiaojing Li, Yunhai Tu, Wentao Yan, Jianzhang Wu, Mao Ye, Wencan Wu   +16 more
wiley   +1 more source

Outcomes of Patients With Thyroid Eye Disease Partially Treated With Teprotumumab

, 2023
In response to the coronavirus (COVID-19) pandemic, teprotumumab production was temporarily halted with resources diverted toward vaccine production. Many patients who initiated treatment with teprotumumab for thyroid eye disease were forced to deviate ...
Burkat, Cat N, Holds, John B, Matthew Sniegowski, Sears, Connie M, Do, Thai H, Wendy W. Lee, Luv G. Patel, Connie M. Sears, Thai H. Do, Magazin, Maja, Malik, Amina I, Sara T. Wester, Shinder, Roman, Robi N. Maamari, Daniel B. Rootman, Alon Kahana, Edith R. Reshef, Compton, Christopher J, Mokhtarzadeh, Ali, Ho, Tiffany C, Lee, Wendy W, Hwang, Christopher J, Maja Magazin, Reshef, Edith R, Avila, Sarah A, Steven M. Couch, Peter Kally, Amina I. Malik, Kahana, Alon, Sniegowski, Matthew, Ali Mokhtarzadeh, Mark J. Lucarelli, Stefania B. Diniz, Andrea L. Kossler, Patel, Luv G, Dilip A. Thomas, Lucarelli, Mark J, Kevin D. Clauss, John B. Holds, Freitag, Suzanne K, Christian Briggs, Sarah A. Avila, Kossler, Andrea L, Turner, Sara, Diniz, Stefania B, Harrison, Andrew R, Schlachter, Dianne, Clauss, Kevin D, Couch, Steven M, Hee Joon Kim, Sara Turner, Rootman, Daniel B, Tiffany C. Ho, Roman Shinder, Dianne Schlachter, Christopher J. Compton, Maamari, Robi N, Kim, Hee Joon, Cat N. Burkat, Andrew R. Harrison, Christopher J. Hwang, Wester, Sara T, Kally, Peter, Briggs, Christian, Suzanne K. Freitag, Thomas, Dilip A   +65 more
core   +1 more source

Graves' disease complicated by concurrent thyroid eye disease and pretibial myxedema successfully treated with teprotumumab

Clinical Case Reports, 2022
We report a 51‐year‐old woman with thyroid eye disease and biopsy‐proven pretibial myxedema that was subsequently treated with teprotumumab with improvement.
Brendan K. Bowens, Eva Chou, David P. LaChance, James R. Huynh, Patrick Voorhees, Thanh C. Do, Mohamed K. M. Shakir, Thanh D. Hoang   +7 more
doaj   +1 more source

Unmasking Orbital Myopathy: When Enlarged Extraocular Muscles Indicate More Than Thyroid Eye Disease: Report of Two Cases

Case Reports in Ophthalmological Medicine, Volume 2026, Issue 1, 2026.
Introduction Orbital myopathy is a condition involving the extraocular muscles, and establishment of a differential diagnosis is crucial to determine its etiology. However, the broad spectrum of the etiologies and the overlap in their clinical and radiological findings often make the diagnosis challenging.
Daisuke Shinohara, Muhammad Abumanhal, Yasuhiro Takahashi, Karuna Sharma   +3 more
wiley   +1 more source

Exploring the Therapeutic Mechanism of Xiehuo Pingtu San in Treating Thyroid Eye Disease Based on Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation

International Journal of Endocrinology, Volume 2026, Issue 1, 2026.
Background Xiehuo Pingtu San (XHPTS) has been shown to be safe and effective in treating thyroid eye disease (TED), yet its underlying mechanisms remain unclear. This study aimed to elucidate the active ingredients of XHPTS and their therapeutic mechanisms in TED through network pharmacology, molecular docking, and molecular dynamics simulations ...
Ping Wang, Ruiyan Liu, Xin Shang, Yu Fu, Ying Wang, Shuxun Yan, Suraiya Saleem   +6 more
wiley   +1 more source

PDGFRα+DPP4+ Fibroblasts‐Macrophage Crosstalk Induces Orbital Fibrosis in Treatment‐Resistant Thyroid Eye Disease via the GAS6‐AXL Pathway

Advanced Science, Volume 12, Issue 45, December 4, 2025.
This study elucidates macrophage‐induced orbital fibrosis in TED via the GAS6‐AXL pathway, a treatment‐resistant disorder lacking non‐surgical therapies. Using a novel patient cell‐derived orthotopic animal model of orbital fibrosis for TED, we repurpose an existing fibrosis therapy, addressing the absence of stable models and offering a potential ...
Lu Cheng, Jinwei Cheng, Guiling Liang, Xiaorui Wang, Yanwen Ge, Jiapei Liu, Luwei Cai, Hui Ying, Fenfen Wang, Jing Hu, Yufan Wang, Philipp E. Scherer, Ben Zhou, Mengle Shao, Fang Zhang   +14 more
wiley   +1 more source

Teprotumumab for Thyroid Eye Disease-related Strabismus [PDF]

PURPOSE: To assess and quantify teprotumumab's effect on thyroid eye disease-related strabismus by change in measured horizontal and vertical deviations and change in extraocular motility.
Dallalzadeh, Liane O, Rootman, Daniel B, Robbins, Shira L, Chen, Lillian, Khitri, Monica R, Velez, Federico G, Villatoro, George A, Demer, Joseph L, Movaghar, Mansoor, Karlin, Justin N, Kikkawa, Don O, Sim, Myung S, Korn, Bobby S, Granet, David B   +13 more
core   +1 more source

A randomised, double-masked, placebo-controlled trial evaluating the efficacy and safety of teprotumumab for active thyroid eye disease in Japanese patientsResearch in context

The Lancet Regional Health. Western Pacific
Summary: Background: Teprotumumab significantly improved proptosis and diplopia in patients with active, moderate-to-severe thyroid eye disease (TED) in previous North American and European studies. This is the first evaluation of efficacy and safety of
Yuji Hiromatsu, Eri Ishikawa, Ai Kozaki, Yasuhiro Takahashi, Mika Tanabe, Ken Hayashi, Yukihiro Imagawa, Kazutoyo Kaneda, Masashi Mimura, Xiaoxian Dai, Tomoko Hayashida, Takashi Akamizu   +11 more
doaj   +1 more source